Mounjaro and Sleep Apnoea: Effects, Safety and Management

Mounjaro (tirzepatide) is a dual GIP and GLP-1 receptor agonist licensed in the UK for type 2 diabetes and weight management in adults with obesity or overweight with comorbidities. Obstructive sleep apnoea (OSA) is strongly linked to obesity, with excess weight contributing to airway obstruction during sleep. Emerging evidence suggests that Mounjaro and sleep apnoea are connected through the medication's weight-loss effects, which may lead to meaningful improvements in OSA severity. However, Mounjaro is not licensed specifically for sleep apnoea treatment, and patients require careful monitoring alongside established therapies such as CPAP.

What Is Mounjaro and How Does It Work?

Mounjaro (tirzepatide) is a prescription medicine licensed in the UK for the treatment of type 2 diabetes mellitus and, more recently, for weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity. It belongs to a novel class of medications known as dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists. This dual mechanism distinguishes Mounjaro from other GLP-1 receptor agonists currently available.

The medication works by mimicking the action of two naturally occurring incretin hormones. GLP-1 stimulates insulin secretion when blood glucose levels are elevated, suppresses glucagon release (which reduces glucose production by the liver), slows gastric emptying, and promotes satiety through central appetite regulation. GIP complements these effects by enhancing insulin secretion and may influence fat metabolism, though its effects on energy expenditure in humans require further research.

Mounjaro is administered as a once-weekly subcutaneous injection. Treatment starts with 2.5 mg weekly for 4 weeks as an initiation dose, then increases in 2.5 mg increments at intervals of at least 4 weeks to a maintenance dose ranging from 5 mg to 15 mg, depending on individual response and tolerability. The MHRA approved tirzepatide following clinical trials demonstrating substantial reductions in HbA1c levels and body weight compared to placebo and other diabetes medications.

The weight loss achieved with Mounjaro can be clinically significant, with higher doses (15 mg) associated with greater effects. In clinical trials, patients without diabetes typically experienced more substantial weight reduction than those with type 2 diabetes. This weight reduction has important implications for obesity-related comorbidities, including cardiovascular disease, non-alcoholic fatty liver disease, and obstructive sleep apnoea (OSA), making the relationship between Mounjaro and sleep-disordered breathing particularly relevant for both patients and clinicians.

Mounjaro®

Average 22.5% body weight loss

Mounjaro® is the most innovative GLP-1 medication proven to dramatically curb appetite, hunger, and cravings to help professional men achieve substantial weight loss.

Start Here

Wegovy®

Average 16.9% body weight loss

Wegovy® is a weekly injectable GLP-1 medication with proven effectiveness in reducing appetite, hunger, and cravings to help busy professionals lose significant weight.

Start Here

Find out if you’re eligible

The Link Between Mounjaro and Sleep Apnea

Obstructive sleep apnoea (OSA) is a common sleep disorder characterised by repeated episodes of partial or complete upper airway obstruction during sleep, leading to intermittent hypoxia, sleep fragmentation, and daytime symptoms such as excessive sleepiness. Obesity is the single most important modifiable risk factor for OSA, with excess adipose tissue around the neck and pharynx contributing to airway narrowing and collapse during sleep.

OSA severity is typically classified based on the apnoea-hypopnoea index (AHI): mild (5-14 events/hour), moderate (15-29 events/hour), or severe (≥30 events/hour).

The connection between Mounjaro and sleep apnoea centres primarily on the medication's weight-loss effects. Clinical evidence suggests that weight reduction of 10–15% can lead to meaningful improvements in OSA severity, though complete resolution is not guaranteed, particularly in moderate to severe cases. The SURMOUNT clinical trial programme, which evaluated tirzepatide for weight management, included some participants with obesity-related comorbidities including OSA.

Recent clinical trials specifically examining tirzepatide in patients with obesity and moderate-to-severe OSA have demonstrated significant reductions in the apnoea-hypopnoea index (AHI). Participants treated with Mounjaro showed decreases in AHI scores alongside considerable weight loss, with improvements in oxygen saturation levels during sleep and reductions in daytime sleepiness as measured by the Epworth Sleepiness Scale.

It is important to note that whilst Mounjaro may improve OSA through weight reduction, it is not licensed specifically as a treatment for sleep apnoea. The improvements observed are secondary to metabolic and weight-related benefits rather than direct effects on upper airway anatomy or neuromuscular function. NICE guidance emphasises that weight management should form part of a comprehensive approach to OSA treatment, with continuous positive airway pressure (CPAP) therapy remaining the first-line treatment for moderate to severe OSA. Other options include mandibular advancement devices or, in selected cases, surgical intervention.

Safety Considerations for Sleep Apnea Patients Taking Mounjaro

Patients with sleep apnoea considering Mounjaro therapy require careful clinical assessment and ongoing monitoring. Whilst the medication offers potential benefits through weight reduction, several safety considerations warrant attention from both prescribers and patients.

Gastrointestinal adverse effects are the most commonly reported side effects of Mounjaro, including nausea, vomiting, diarrhoea, constipation, and abdominal discomfort. These effects are typically mild to moderate, dose-dependent, and tend to diminish over time. However, for patients with OSA who may already experience gastro-oesophageal reflux disease (GORD)—a common comorbidity—these gastrointestinal symptoms could potentially exacerbate nocturnal reflux and worsen sleep quality. Patients should be advised to:

• Take the medication at a consistent time each week

• Eat smaller, more frequent meals

• Avoid lying down immediately after eating

• Report persistent or severe gastrointestinal symptoms to their GP

Hypoglycaemia risk is generally low with Mounjaro monotherapy but increases when combined with insulin or sulfonylureas. Blood glucose monitoring should be optimised, and concomitant diabetes medications may require dose adjustment. Combining Mounjaro with DPP-4 inhibitors is not recommended.

There is no evidence that Mounjaro worsens sleep apnoea; however, weight loss can alter airway anatomy, potentially requiring re-titration of CPAP pressure settings. Patients using CPAP therapy should maintain regular follow-up with sleep medicine services during significant weight loss.

Important safety information includes:

• Contraception: Mounjaro may reduce the effectiveness of oral contraceptives. Additional contraception is recommended for 4 weeks after starting treatment and after each dose increase.

• Pregnancy and breastfeeding: Mounjaro is not recommended during pregnancy or breastfeeding. Women of childbearing potential should use effective contraception and discontinue treatment at least one month before a planned pregnancy.

• Gallbladder disease: Tirzepatide has been associated with an increased risk of gallbladder-related disorders, including cholelithiasis and cholecystitis.

• Dehydration and acute kidney injury: Gastrointestinal side effects may lead to dehydration, potentially causing acute kidney injury. Adequate fluid intake is essential.

• Diabetic retinopathy: Patients with a history of diabetic retinopathy should be monitored closely, particularly if rapid improvement in glucose control occurs.

Patients should be advised to report suspected adverse reactions to the MHRA Yellow Card Scheme.

Managing Sleep Apnea While Using Mounjaro

Effective management of sleep apnoea in patients taking Mounjaro requires a multidisciplinary, integrated approach that addresses both conditions simultaneously whilst monitoring for interactions and optimising therapeutic outcomes.

Continuation of existing OSA treatment is essential. Patients already using CPAP therapy, mandibular advancement devices, or other interventions should maintain these treatments even as they begin Mounjaro. Weight loss does not produce immediate improvements in OSA, and discontinuing proven therapies prematurely could result in recurrence of symptoms and associated cardiovascular risks. As weight reduces, patients should:

• Attend scheduled follow-up appointments with sleep services

• Report any changes in mask fit or comfort (weight loss may alter facial contours)

• Monitor for signs that CPAP pressure may need adjustment (mask leaks, persistent symptoms)

• Consider repeat sleep studies after significant weight loss (typically >10% body weight) to reassess OSA severity

Lifestyle modifications complement both Mounjaro therapy and OSA management. NICE recommends a comprehensive approach including:

• Dietary optimisation: Working with dietitians to maximise nutritional quality whilst managing Mounjaro-related appetite changes

• Physical activity: Gradual increase in exercise as tolerated, which independently improves OSA severity and enhances weight loss

• Sleep hygiene: Maintaining regular sleep schedules, optimising bedroom environment, and avoiding alcohol (which worsens OSA)

• Positional therapy: Sleeping on one's side rather than supine can reduce OSA severity in some patients

Monitoring and follow-up should include regular assessment of:

• Weight and body mass index (BMI)

• Glycaemic control (HbA1c, glucose monitoring)

• OSA symptoms (daytime sleepiness, snoring, witnessed apnoeas)

• Tolerability of Mounjaro (gastrointestinal symptoms, injection site reactions)

• Cardiovascular risk factors (blood pressure, lipid profile)

Driving considerations are important for patients with OSA. The DVLA advises that patients must stop driving and inform the DVLA if they experience excessive daytime sleepiness that affects their driving. Driving may resume once symptoms are effectively controlled with treatment. Commercial drivers face stricter requirements and should seek specific guidance.

Patients should be advised to contact their GP if they experience worsening daytime sleepiness, morning headaches, difficulty concentrating, or mood changes, as these may indicate inadequately controlled OSA requiring urgent review. Similarly, severe or persistent side effects from Mounjaro warrant medical assessment and possible dose adjustment or treatment discontinuation.

Frequently Asked Questions